Examining Investor Sentiment Towards Inspire Medical Systems

This afternoon we watched Inspire Medical Systems drop -5.1% to a price of $194.0 per share. The Mid-Cap Medical Instruments & Supplies company is now trading -23.28% below its average target price of $252.87. Analysts have set target prices ranging from $187.0 to $280.0 per share for Inspire Medical Systems, and have given the stock an average rating of buy.

Inspire Medical Systems has an average level of shares sold short, at 6.7% of its total share float. The stock's short ratio (also called days to cover) is 3.17. Since 1.72% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.

Institutional investors own 106.7% of Inspire Medical Systems's shares, which indicates they have a high level of confidence in the company.

Institutions Invested in Inspire Medical Systems

Date Reported Holder Percentage Shares Value
2023-12-31 FMR, LLC 11% 3,257,544 $631,963,536
2023-12-31 Vanguard Group Inc 10% 2,931,469 $568,704,986
2023-12-31 Blackrock Inc. 6% 1,800,207 $349,240,158
2023-12-31 Wellington Management Group, LLP 5% 1,430,266 $277,471,604
2023-12-31 Baillie Gifford and Company 4% 1,229,879 $238,596,526
2023-12-31 Wasatch Advisors LP 4% 1,097,345 $212,884,930
2023-12-31 Farallon Capital Management LLC 3% 855,096 $165,888,624
2023-12-31 William Blair Investment Management, LLC 3% 806,947 $156,547,718
2023-12-31 Frontier Capital Management Company LLC 3% 742,046 $143,956,924
2023-12-31 Champlain Investment Partners, LLC 2% 648,595 $125,827,430
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.